The Psychiatrist: Clinical and Therapeutic Journal

Review Article Open Access

A Study on the Vulnerability of Parkinson's Disease and how it Relates to Early Dementia

Rabiul Ahasan*

Institute of Clinical Neurobiology, Innsbruck Medical University, Austria

Abstract

Patients with Parkinson's disease (PD) have gotten little attention, even though suspicion is thought to be a clinical condition linked to greater susceptibility to adverse health outcomes. In this study, we examined the relationship between frailty risk in de novo PD patients and future dementia. When age-related problems and other chronic conditions come together, people with Parkinson's disease (PD) may also face a rapid functional decline. This process of deficit buildup ultimately has an impact on the tissues, organs, and coordinated organ action, especially under stress. Parkinson's disease (PD) is characterized by a wide spectrum of potentially incapacitating motor and non-motor symptoms, including dementia.

Introduction

Slightness is characterized by a reduced capacity for many physiological systems to self-balance out in response to external forces, increased helplessness to stretch, and increased risk of unfavorable health outcomes like disability, dependency, low quality of life, and passing. There are many tools available for measuring frailty, however the Broiled's aggregate, and the Feebleness List (FI) are the two most popular assessments. Whatever the method employed to portray a person as weak and its variations, susceptibility has been found to foretell a few unfavorable results in more mature people. Additionally, it has been demonstrated that fragility is a distinct predictor of dementia overall, Alzheimer's disease, cognitive decline, and neuropathologic burden. the illness Parkinson's (PD). Frailty has been associated with functional, structural, and pathological alterations in the brain. Additionally, there is evidence that suggests treatments for or prevention of frailty may be able to delay or prevent adverse health effects. Despite this, little research has been done on the idea of frailty in Parkinson's disease patients, which is why this patient population has not been looked at for therapies of this nature [1-3]. Considering this, we looked into the association between the prevalence of fragility in early PD and the propensity for dementia, one of the disease's most severe consequences. It is necessary to identify dementia predictors for patients, their families, and the healthcare system. Age, the severity of motor symptoms, and other demographic and clinical traits have all been associated to dementia, but little is known about frailty in this population.

Materials and techniques

This long term optional inquiry focuses on the Norwegian Park West project, a forthcoming population-based, longitudinal, multicenter partner study designed to investigate the prevalence, pathophysiology, and prognosis of PD patients. The recruitment methods and study layout have already been thoroughly covered. A few of the search techniques for potential members included evaluating emergency clinic data sets, reference letters, and notice of local clinics and health professions. Our main goal was to compile a list of every new instance of Parkinson's disease (PD) discovered in Western and Southern Norway between November 2004 and September 2006.

The Western Norway Regional Committee for Medical and Health Research Ethics approved the study, which was conducted in conformity with the Helsinki Declaration. Prior to taking part in the trial, each subject provided written, informed consent. Participants and Aftercare In this study, 192 newly diagnosed drug-naive Parkinson's disease patients who satisfied the clinical criteria of the Gelb and UK Parkinson's Disease Society Brain Bank Parkinson's disease were included. None of these patients had a history of dementia within a year of the beginning of motor function. The No-PD group included 171 healthy persons who were free of parkinsonism, dementia, or major depression at the time of study and were matched for age, gender, and education. The entire group was Caucasian.

Under the supervision of competent health professionals, a scheduled evaluation program was provided to both patients and controls at baseline, one year, and three years of follow-up, respectively. At standard, we gathered information on economics, clinical history, and comorbidities while visiting a parental figure whenever circumstances permitted, and we conducted semi-coordinated interviews as well as a general clinical and neurological evaluation. Clinical and neuropsychological evaluation Data from current conclusions at pattern and during the review period were used for additional tests (see Susceptibility section) to obtain a full picture of the segment and clinical status of the patients included . Two neurologists who specialize in movement disorders used standardized criteria and tests to make the novel diagnosis of Parkinson's disease (PD) (see Participants and Follow-up section). Similarly, the published consensus criteria were used to identify dementia associated with Parkinson's disease (PDD), and the diagnosis was reevaluated during follow-up.

The motor examination subscale (part III) of the Unified Parkinson's Disease Rating Scale (UPDRS) was used to assess motor severity. To assess neuropsychiatric side effects, the Norwegian version of the Neuropsychiatric Stock (NPI) 12 items and its NPI absolute score were employed. The Mini-Mental State Examination (MMSE) was used to test global cognition [4]. The Short Form Health Survey (SF36) was used

***Corresponding author:** Rabiul Ahasan, Institute of Clinical Neurobiology, Innsbruck Medical University, Austria, Tel: 1187421953230; E-mail: RabiulA@gmail.com

Received 03-Apr-2023, Manuscript No tpctj-23-96811; **Editor assigned:** 05-Apr-2023, PreQC No. tpctj-23-96811 (PQ); **Reviewed:** 19-Apr-2023, QC No tpctj-23-96811; **Revised:** 22-Apr-2023, Manuscript No. tpctj-23-96811 (R); **Published:** 29-Apr-2023, DOI: 10.4172/tpctj.1000179

Citation: Ahasan R (2023) A Study on the Vulnerability of Parkinson's Disease and how it Relates to Early Dementia. Psych Clin Ther J 5: 179.

to assess global health-related quality of life. A more comprehensive depiction of the Park West partner's conclusion of PD and PDD, as well as separate organized assessments for engine and non-engine side effects, may be found elsewhere. Furthermore, patients undertook a neuropsychological battery of tests assumed to be minimally influenced by motor performance to examine cognitive domains known to be impaired in Parkinson's disease. The neuropsychological battery assessed verbal memory, attention, executive functioning, and visuospatial skills. After 20 minutes, the California Verbal Learning Test II was used to assess verbal memory utilizing total instantaneous recall, short delay free recall, and long delay free recall. The Visual Object and Space Perception Battery's Silhouettes and Cube subtests were used to assess participants' visual and spatial abilities. The Stroop test's sum of color and word conditions, the MMSE's verbal fluency in one minute test, and the MMSE's serial 7 test were all used to assess attention and executive skills. There is more information regarding the neuropsychological assessment available elsewhere.

Fragility, according to Searle et al. To determine baseline frailty, we employed the FI approach, and its criteria for including health-related factors and inadequacies were met. The FI is a widely used tool that has been used in a variety of clinical, research, and demographic contexts.

The FI is chosen using the following criteria:

1) Excluding candidate deficits unrelated to age

2) Excluding deficits whose prevalence is either too low or too high to be informative.

3) Excluding potential deficit variables missing more than 5% of the data

4) Excluding participants missing more than 20% of the variable data in the FI.

All of these characteristics help to rule out probable deficit variables. Any health characteristic whose scarcity or less secure status increases with age and is connected to death or other annoying outcomes of interest, for example, hospitalization or admission to a nursing home, is considered a health deficiency.

- High blood pressure
- High blood pressure
- Arrhythmia or swell
- Hypercholesterolemia
- Depression
- Nervousness
- Heart failure number eight Necrosis of the myocardium
- COPD after a stroke
- Diabetes mellitus (Type 2)
- Ulcer disease
- Renal cancer infection
- Rheumatoid arthritis
- Unable to drive
- Difficulties urinating
- Indigestion Sleepiness during the day
- Torment in any part of your body in the last month
- Tiredness
- Problems with dressing alone Issues with self-cleaning
- Food falls and an inability to perform
- Moderate-intensity activities, such as lifting a table, vacuuming, bowling, or walking for more than an hour
- Take or carry the shopping bag.
- Climb the steps a few stories up.
- Kneeling or crouching

Two factors were assigned a value of zero (no deficiency) or one (setback). Variables with more than two replies accounted for a percentage of the total shortfall coded.

• Early neurodegenerative markers can be used to predict who will acquire dementia.

• Susceptibility is common in patients with Parkinson's disease who have recently been evaluated.

• In Parkinson's disease, weakness is linked to an increased risk of dementia later in life.

• The importance of mild Parkinson's disease (PD) from the earliest clinical stages is highlighted in this review.

As far as anybody is aware, this is the first study to examine the relationship between mild cognitive impairment and dementia in PD patients who have recently been diagnosed with the illness. Higher baseline FI was associated with a higher adjusted likelihood of acquiring PDD, and patients with a de-novo diagnosis of PD had a higher adjusted likelihood of presenting with a high FI [5]. These two groups were contrasted with controls. Frailty is an age-related deterioration in a person's physiological abilities. It is characterized by greater vulnerability and a greater likelihood of experiencing negative health effects. Protective factors minimize this risk in proportion to how many health problems a person has. The clinical significance of fragility has been demonstrated in several different diseases, including COPD, diabetes, malignant growth, and Alzheimer's. Indeed, PD patients exhibit both motor and nonmotor side effects, a wide range of comorbidities, and related practical limitations even in its early stages. According to a recent purposeful survey, five exams of PD patients confirmed the existence of weakness.

Even though recent findings suggest that persons with Parkinson's disease tend to be frail, estimates of what qualifies as fragility may be off. Frailty has consistently been found to be a substantial predictor of negative outcomes, both overall and disease-specific, across several diseases, contexts, and locations, regardless of the estimating tool or criteria . Medicare beneficiary research in the US discovered that people with Parkinson's disease who were extremely fragile had a higher probability of passing away, being hospitalized, using the emergency room, and falling. Frailty has been shown to negatively affect significant patient-reported outcomes like quality-of-life ratings in community-dwelling PD patients.

Dementia is a terrible occurrence for those who have Parkinson's disease, their families, and their parents. Furthermore, a strong advocate for a decline in capability that leads to dependence. Increased carer burden, growing healthcare and institutionalization expenses, a decline in wellbeing, and an increase in mortality have all been connected to

cognitive decline. Patients with Parkinson's disease must therefore determine the causes of dementia and cognitive deterioration. Early biomarkers and PDD symptoms, such as frailty, are essential because they could be prevented by early intervention with modifiable targets. Only one cross-sectional investigation has examined the relationship between dementia and PD fragility; it indicated that dementia odds ratios were 9–11 times higher in frail PD patients with long-term PD. In the current investigation, we discovered that those with higher FI at the drug-naive PD diagnosis were more likely to get PDD [6-9]. This implies that FI may eventually act as a precursor to the start of PDD. Our results support earlier research on Alzheimer's disease, which has demonstrated that frailty can predict dementia even after correcting for the specific load of Alzheimer pathology and other neuropathological indicators associated with dementia.

Conclusion

We agree that some FI variables, such as the inability to cut food, are typical of PD and may lead to circular connections or inflated FI scores. Since evaluating feebleness was not initially anticipated for the Park west study, the FI used in this study had to be gauge-determined and had to consider a predefined number of deficits. The three-year concentration period might not be long enough to introduce the outcome because PDD risk increases with PD duration. The longitudinal design of the study and the inclusion of drug-naive patients are its strengths; as a result, all FI variables were measured devoid of any possible PD medication-related effects. Our decisions are aided by the inclusion of a control group without PD, the normalized approach for clinical PD and PDD findings, and the low steady loss rate during follow-up.

References

1. Bodnar AG (1998) Extension of lifespan by introduction of telomerase into normal human cells. Science 279(5349): 349-352.
2. Von Zglinicki T (2002) Oxidative stress shortens telomeres. Trends Biochem Sci 27: 339-344.
3. Bartkova J (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444(7119): 633-637.
4. Eischen CM, Lozano G (2014). The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat 35: 728-737.
5. Yosef R, et al (2016). Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun 7: 11190.
6. Flavie W, Charles F (2017) Hallucinations: A Systematic Review of Points of Similarity and Difference Across Diagnostic Classes. Schizophr Bull 43: 32-43.
7. Siu WT, Wayne HT (2020) Hallucinations: diagnosis, neurobiology and clinical management. Int Clin Psychopharmacol 35: 293-299.
8. Charles F (2019) Modality-general and modality-specific processes in hallucinations. Psychol Med 49: 2639-2645.
9. Renaud J, Kenneth H, Matthew H, Jerome B, Flavie W, et al. (2016) Are Hallucinations Due to an Imbalance Between Excitatory and Inhibitory Influences on the Brain?. Schizophr Bull 42: 1124-1134.